Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrous interstitial lung disease of unknown etiology. IPF is also considered to be among the independent risk factors for lung cancer, increasing the risk of lung cancer by 7% and 20%. The incidence of IPF complicated with lung cancer, especially non-small cell lung cancer (NSCLC), is increasing gradually, but there is no consensus on unified management and treatment. IPF and NSCLC have similar pathological features. Both appear in the surrounding area of the lung. In pathients with IPF complicated with NSCLC, NSCLC often develops from the honeycomb region of IPF, but the mechanism of NSCLC induced by IPF remains unclear. In addition, IPF and NSCLC have similar genetic, molecular and cellular processes and common signal transduction pathways. The universal signal pathways targeting IPF and NSCLC will become potential therapeutic drugs for IPF complicated with NSCLC. This article examines the main molecular mechanisms involved in IPF and NSCLC and the research progress of drugs under development targeting these signal pathways. .
【中文题目：特发性肺纤维化合并非小细胞肺癌的致病机制及潜在治疗药物研究进展】 【中文摘要：特发性肺纤维化（idiopathic pulmonary fibrosis, IPF）是病因不明的慢性进行性纤维化性间质性肺疾病，IPF也被认为是肺癌的独立风险因素之一，可增加7%-20%的LC发病风险。IPF合并LC，尤其是非小细胞肺癌（non-small cell LC, NSCLC）的发病率逐渐升高，但尚无统一的管理和治疗共识。IPF与NSCLC有着相似的病理特征，均在肺的周围区域出现，在IPF合并NSCLC的患者中，NSCLC往往从IPF的蜂窝区域发展而来，但IPF诱发NSCLC的机制仍不清楚。此外，IPF和NSCLC具有相似的遗传、分子和细胞过程以及常见的信号转导通路，靶向IPF和NSCLC共同的信号通路将成为IPF合并NSCLC的潜在治疗药物。本文就针对共同参与IPF和NSCLC的主要分子机制以及靶向这些信号通路的在研药物的研究进展进行综述。 】 【中文关键词：特发性肺纤维化；肺肿瘤；致病机制；治疗药物】.
Keywords: Idiopathic pulmonary fibrosis; Lung neoplasms; Pathogenesis; Therapeutic drug.